- Home
- CNTB vs LRE Comparison
CNTB vs LRE Comparison
Compare CNTB & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- LRE
- Stock Information
- Founded
- CNTB 2012
- LRE 2001
- Country
- CNTB United States
- LRE Japan
- Employees
- CNTB N/A
- LRE N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- LRE
- Sector
- CNTB Health Care
- LRE
- Exchange
- CNTB Nasdaq
- LRE Nasdaq
- Market Cap
- CNTB 44.2M
- LRE 17.6M
- IPO Year
- CNTB 2021
- LRE 2023
- Fundamental
- Price
- CNTB N/A
- LRE N/A
- Analyst Decision
- CNTB Strong Buy
- LRE
- Analyst Count
- CNTB 2
- LRE 0
- Target Price
- CNTB $7.50
- LRE N/A
- AVG Volume (30 Days)
- CNTB 103.1K
- LRE 14.8K
- Earning Date
- CNTB 05-15-2025
- LRE 01-01-0001
- Dividend Yield
- CNTB N/A
- LRE N/A
- EPS Growth
- CNTB N/A
- LRE N/A
- EPS
- CNTB N/A
- LRE N/A
- Revenue
- CNTB $26,033,000.00
- LRE $110,330,328.00
- Revenue This Year
- CNTB N/A
- LRE N/A
- Revenue Next Year
- CNTB N/A
- LRE N/A
- P/E Ratio
- CNTB N/A
- LRE N/A
- Revenue Growth
- CNTB N/A
- LRE 8.82
- 52 Week Low
- CNTB $0.51
- LRE $1.10
- 52 Week High
- CNTB $1.60
- LRE $2.49
- Technical
- Relative Strength Index (RSI)
- CNTB 72.64
- LRE 57.65
- Support Level
- CNTB $1.02
- LRE $1.71
- Resistance Level
- CNTB $1.07
- LRE $2.11
- Average True Range (ATR)
- CNTB 0.09
- LRE 0.12
- MACD
- CNTB 0.01
- LRE -0.01
- Stochastic Oscillator
- CNTB 91.19
- LRE 34.69
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.